UWKI yields 200000000.00% · ABBV yields 3.06%● Live data
📍 UWKI pulled ahead of the other in Year 1
Combined, UWKI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UWKI + ABBV for your $10,000?
uWink Inc. Del develops and operates digital media entertainment and hospitality software. It also develops and operates an interactive restaurant concept under the name uWink that incorporates and showcases its entertainment and hospitality software. It offers Hospitality ordering, a touch-based user interface that allows users to self-order various food and drink through touch screen terminals; Self check in/checkout software, which enables users to self-check in and checkout at the table using a credit card or pre-paid debit card; and Multi-player game platform, which allows users to play digital games in real time. The company also provides uWink Game Library that features single and multi-player short-form, casual, and social video games; Micro-transaction game play monetization software for game credit purchasing, tracking, and redemption; Media display system, which exhibits revolving imagery for restaurants to change its look and feel. In addition, it licenses SNAP!, a countertop video game platform; and Bear Shop, an entertainment vending platform to third party manufacturers. Its restaurant menu features a selection of appetizers, entrees, pizzas, burgers, salads, pastas, and desserts. The company was incorporated in 1999 and is based in Van Nuys, California.
Full UWKI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.